NEW YORK – Q-State Biosciences and the 2bPrecise unit of Allscripts Healthcare Solutions said today that they have agreed to collaborate on building clinical-genomic datasets to support the practice of precision medicine.
With their partnership, the two technology vendors hope to produce insights that care providers can apply to clinical practice and that pharmaceutical companies can use to develop novel therapies.
Pittsburgh-based 2bPrecise will contribute its cloud-based technology platform that integrates genomic data into clinical workflows. Q-State, of Cambridge, Massachusetts, is offering whole-genome and whole-exome sequencing, as well as transcriptomics analysis and phenotyping services to the partnership.
"This partnership facilitates healthcare innovation that enables precision medicine and genetically based clinical care on a transformative scale," 2bPrecise Founder and CEO Assaf Halevy said in a statement.
"Genomic data holds the power to evolve the entire healthcare industry. Today, patients' genetic information enables not only diagnoses, but also systematic identification of disease targets and synthesis of new genetically targeted medicines," added Q-State CEO Matthew Fox.
Terms of the deal were not disclosed.